New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
10:00 EDTUSB, IMO, EIX, MDCO, HSTM, ONB, NDZ, ESSOn The Fly: Analyst Downgrade Summary
ArcelorMittal (MT) downgraded to Neutral from Outperform at Credit Suisse... Essex Property Trust (ESS) downgraded to Neutral from Buy at Goldman... Healthstream (HSTM) downgraded to Market Perform from Outperform at Northland... Imperial Oil (IMO) downgraded to Underperform from Neutral at BofA/Merrill... Nordion (NDZ) downgraded to Hold from Buy at Canaccord... The Medicines Co. (MDCO) downgraded to Neutral from Overweight at Piper Jaffray... U.S. Bancorp (USB) downgraded to Hold from Buy at Sandler O'Neill... Old National Bancorp (ONB) downgraded to Hold from Buy at Sandler O'Neill... Edison International (EIX) downgraded to Hold from Buy at Argus.
News For ESS;HSTM;IMO;NDZ;MDCO;USB;ONB;EIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 28, 2014
06:43 EDTUSBU.S. Bancorp unit sued for not helping borrowers, NY Times reports
Subscribe for More Information
November 24, 2014
07:01 EDTUSBFed could further restrict banks' commodities businesses, NY Times says
Subscribe for More Information
November 21, 2014
07:24 EDTUSBBB&T CEO says 'banks lending recklessly' again, Reuters reports
Subscribe for More Information
November 20, 2014
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
07:51 EDTUSBClearing House Payments Company to hold a conference
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use